Not available outside of the UK & Ireland.
Application
The reagent is designed for Flow Cytometry analysis of human blood cells using 20 µL reagent / 100 µL of whole blood or 1e6 cells in a suspension. The content of a vial (2 mL) is sufficient for 100 tests.
Biochem/physiol Actions
Cluster of differentiation 41 (CD41) is significantly involved in platelet adhesion and thrombus formation at the location of vascular injury. Fibrinogen and many extracellular matrix proteins bind in a groove between the α and β-subunits of the integrin receptor. Platelet aggregation, induced by the binding of fibrinogen to the ITGA2B receptor, is involved in the pathogenesis of acute thrombosis in coronary heart disease, stroke and peripheral arterial disease. CD41, expressed in haematopoietic progenitors, is associated with erythroid activity and endothelial marker expression. Single-nucleotide polymorphisms (SNPs) in CD41 might be associated with the risk of acute coronary syndrome and atherosclerosis.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
General description
Cluster of differentiation 41 (CD41), also known as integrin subunit α 2b (ITGA2B) or GPIIb/IIIa (glycoprotein), is encoded by the gene mapped to human chromosome 17q21.31. It is a platelet-specific, surface membrane receptor.
The antibody MEM-06 reacts with CD41 (GPIIb), a transmembrane glycoprotein (integrin family) composed of two chains GPIIb alpha (heavy chain; 120 kDa) and GPIIb beta (light chain; 23 kDa). CD41 is mainly expressed on platelets and megakaryocytes.
Immunogen
Leukocytes of patient suffering from LGL-type leukaemia
Physical form
Solution in phosphate buffered saline containing 15 mM sodium azide and 0.2% high-grade protease free BSA as a stabilizing agent.
This product has met the following criteria to qualify for the following awards: